173 related articles for article (PubMed ID: 34924498)
41. DLL3 regulates the migration and invasion of small cell lung cancer by modulating Snail.
Furuta M; Kikuchi H; Shoji T; Takashima Y; Kikuchi E; Kikuchi J; Kinoshita I; Dosaka-Akita H; Sakakibara-Konishi J
Cancer Sci; 2019 May; 110(5):1599-1608. PubMed ID: 30874360
[TBL] [Abstract][Full Text] [Related]
42. Drugs in development for small cell lung cancer.
Serzan MT; Farid S; Liu SV
J Thorac Dis; 2020 Oct; 12(10):6298-6307. PubMed ID: 33209468
[TBL] [Abstract][Full Text] [Related]
43. Small cell lung cancer: model of circulating tumor cell tumorospheres in chemoresistance.
Klameth L; Rath B; Hochmaier M; Moser D; Redl M; Mungenast F; Gelles K; Ulsperger E; Zeillinger R; Hamilton G
Sci Rep; 2017 Jul; 7(1):5337. PubMed ID: 28706293
[TBL] [Abstract][Full Text] [Related]
44. Evaluating
Lakes AL; An DD; Gauny SS; Ansoborlo C; Liang BH; Rees JA; McKnight KD; Karsunky H; Abergel RJ
Mol Pharm; 2020 Nov; 17(11):4270-4279. PubMed ID: 33044830
[TBL] [Abstract][Full Text] [Related]
45. Identification of candidate responders for anti-PD-L1/PD-1 immunotherapy, Rova-T therapy, or EZH2 inhibitory therapy in small-cell lung cancer.
Saito M; Saito K; Shiraishi K; Maeda D; Suzuki H; Minamiya Y; Kono K; Kohno T; Goto A
Mol Clin Oncol; 2018 Feb; 8(2):310-314. PubMed ID: 29435295
[TBL] [Abstract][Full Text] [Related]
46. Second-line therapy for small cell lung cancer: exploring the potential role of circulating tumor cells.
Hamilton G; Rath B; Holzer S; Hochmair M
Transl Lung Cancer Res; 2016 Feb; 5(1):71-7. PubMed ID: 26958494
[TBL] [Abstract][Full Text] [Related]
47. Systematic Literature Review of the Prevalence and Prognostic Value of Delta-Like Ligand 3 Protein Expression in Small Cell Lung Cancer.
Bylsma LC; Pundole X; Ju CH; Hooda N; Movva N; Elkhouly E; Bebb G; Fryzek J; Martinez P; Balasubramanian A; Dingemans AC
Target Oncol; 2023 Nov; 18(6):821-835. PubMed ID: 37930513
[TBL] [Abstract][Full Text] [Related]
48. Delta-like ligand 3 in small cell lung cancer: Potential mechanism and treatment progress.
Yang W; Wang W; Li Z; Wu J; Huang X; Li J; Zhang X; Ye X
Crit Rev Oncol Hematol; 2023 Nov; 191():104136. PubMed ID: 37716517
[TBL] [Abstract][Full Text] [Related]
49. CAR NK-92 cells targeting DLL3 kill effectively small cell lung cancer cells in vitro and in vivo.
Liu M; Huang W; Guo Y; Zhou Y; Zhi C; Chen J; Li J; He J; Lian H; Zhou J; Ye X; Hu Y; Hu H; Liu Z; Huang J; Lin L; Cai M; Wang X; Huang J; Zhang Z; Zhu K; Zhao Q; Cao B
J Leukoc Biol; 2022 Oct; 112(4):901-911. PubMed ID: 35088475
[TBL] [Abstract][Full Text] [Related]
50. ADC Shows Effectiveness in SCLC.
Cancer Discov; 2015 Dec; 5(12):OF4. PubMed ID: 26493959
[TBL] [Abstract][Full Text] [Related]
51. Delta-Like Protein 3 Expression and Targeting in Merkel Cell Carcinoma.
Xie H; Kaye FJ; Isse K; Sun Y; Ramoth J; French DM; Flotte TJ; Luo Y; Saunders LR; Mansfield AS
Oncologist; 2020 Sep; 25(9):810-817. PubMed ID: 32372416
[TBL] [Abstract][Full Text] [Related]
52. Design and Synthesis of Tesirine, a Clinical Antibody-Drug Conjugate Pyrrolobenzodiazepine Dimer Payload.
Tiberghien AC; Levy JN; Masterson LA; Patel NV; Adams LR; Corbett S; Williams DG; Hartley JA; Howard PW
ACS Med Chem Lett; 2016 Nov; 7(11):983-987. PubMed ID: 27882195
[TBL] [Abstract][Full Text] [Related]
53. FZ-AD005, A Novel DLL3-Targeted Antibody-drug Conjugate with Topoisomerase I Inhibitor, Shows Potent Antitumor Activity in Preclinical Models.
Guo Q; Gao B; Song R; Li W; Xie Q; Lou S; Shen J; Zhao T; Zhang Y; Wu J; Yang T
Mol Cancer Ther; 2024 Jun; ():. PubMed ID: 38940283
[TBL] [Abstract][Full Text] [Related]
54. Tarlatamab, a First-in-Class DLL3-Targeted Bispecific T-Cell Engager, in Recurrent Small-Cell Lung Cancer: An Open-Label, Phase I Study.
Paz-Ares L; Champiat S; Lai WV; Izumi H; Govindan R; Boyer M; Hummel HD; Borghaei H; Johnson ML; Steeghs N; Blackhall F; Dowlati A; Reguart N; Yoshida T; He K; Gadgeel SM; Felip E; Zhang Y; Pati A; Minocha M; Mukherjee S; Goldrick A; Nagorsen D; Hashemi Sadraei N; Owonikoko TK
J Clin Oncol; 2023 Jun; 41(16):2893-2903. PubMed ID: 36689692
[TBL] [Abstract][Full Text] [Related]
55. Small cell lung cancer: Circulating tumor cells of extended stage patients express a mesenchymal-epithelial transition phenotype.
Hamilton G; Hochmair M; Rath B; Klameth L; Zeillinger R
Cell Adh Migr; 2016 Jul; 10(4):360-7. PubMed ID: 26919626
[TBL] [Abstract][Full Text] [Related]
56. Progress and challenges in the treatment of small cell lung cancer.
Tartarone A; Giordano P; Lerose R; Rodriquenz MG; Conca R; Aieta M
Med Oncol; 2017 Jun; 34(6):110. PubMed ID: 28456992
[TBL] [Abstract][Full Text] [Related]
57. Characteristics of Notch signaling pathway and its correlation with immune microenvironment in SCLC.
Li W; Ye L; Huang Y; Zhou F; Wu C; Wu F; He Y; Li X; Wang H; Xiong A; Gao G; Wang L; Su C; Ren S; Chen X; Zhou C
Lung Cancer; 2022 May; 167():25-33. PubMed ID: 35381444
[TBL] [Abstract][Full Text] [Related]
58. Design of two immunotoxins based rovalpituzumab antibody against DLL3 receptor; a promising potential opportunity.
Ataee MH; Mirhosseini SA; Mirnejad R; Rezaie E; Hosseini HM; Amani J
Res Pharm Sci; 2022 Aug; 17(4):428-444. PubMed ID: 36034078
[TBL] [Abstract][Full Text] [Related]
59. Anticancer Activity of Fascaplysin against Lung Cancer Cell and Small Cell Lung Cancer Circulating Tumor Cell Lines.
Rath B; Hochmair M; Plangger A; Hamilton G
Mar Drugs; 2018 Oct; 16(10):. PubMed ID: 30322180
[TBL] [Abstract][Full Text] [Related]
60. Genomic characteristics and clinical significance of CD56+ circulating tumor cells in small cell lung cancer.
Ricordel C; Chaillot L; Vlachavas EI; Logotheti M; Jouannic A; Desvallees T; Lecuyer G; Aubry M; Kontogianni G; Mastrokalou C; Jouan F; Jarry U; Corre R; Le Guen Y; Guillaudeux T; Lena H; Chatziioannou A; Pedeux R
Sci Rep; 2023 Mar; 13(1):3626. PubMed ID: 36869231
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
